Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewKT 182
说明： Potent, selective and irreversible α/β-hydrolase domain 6 (ABHD6) inhibitor
化学名： [4-[3'-(Hydroxymethyl)[1,1'-biphenyl]-4-yl]-1H-1,2,3-triazol-1-yl](2-phenyl-1-piperidinyl)methanone
纯度： ≥98% (HPLC)
生物活性 for KT 182
KT 182 is a potent, selective and irreversible α/β-hydrolase domain 6 (ABHD6) inhibitor (IC50 = 1.7 nM). KT 182 exhibits selectively for ABHD6 over other brain and liver serine hydrolases, but does exhibit some activity at carboxylesterase-1. KT 182 inhibits ABHD6 activity in the brain and liver in mice following intraperitoneal administration.
技术数据 for KT 182
| 分子量 | 438.53 |
| 公式 | C27H26N4O2 |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 1402612-62-7 |
| PubChem ID | 53364491 |
| InChI Key | GICNKPZHUCVFNM-UHFFFAOYSA-N |
| Smiles | OCC1=CC=CC(C2=CC=C(C3=CN(C(N4CCCCC4C5=CC=CC=C5)=O)N=N3)C=C2)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for KT 182
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 43.85 | 100 |
制备储备液 for KT 182
以下数据基于产品分子量 438.53。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.28 mL | 11.4 mL | 22.8 mL |
| 5 mM | 0.46 mL | 2.28 mL | 4.56 mL |
| 10 mM | 0.23 mL | 1.14 mL | 2.28 mL |
| 50 mM | 0.05 mL | 0.23 mL | 0.46 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for KT 182
参考文献 for KT 182
参考文献是支持产品生物活性的出版物。
Hsu et al (2013) Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6) J.Med.Chem. 56 8270 PMID: 24152295
If you know of a relevant reference for KT 182, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: KT 182, KT 182 supplier, KT182, potent, selective, irreversible, alpha/beta-hydrolase, α/β, alfa, domains, 6, ABHD6, inhibitors, inhibits, MAGL, 6738, Tocris Bioscience
KT 182 的评论
目前没有该产品的评论。 Be the first to review KT 182 and earn rewards!
Have you used KT 182?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Cancer Metabolism Research Product Guide
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Glycolysis
- Tricarboxylic Acid Cycle
- Lipidogenesis
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cannabinoid Receptor Ligands Scientific Review
Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.